Physician profile
Keni A Horiuchi
NPI 1306924592
$1,198.92
in general payments reported to CMS, 2019-2025
13 companies · $457 in 2025
The $457 reported for 2025 was more than what a typical Oncology (Clinical Nurse Specialist) provider received nationally (typical 2025 total: $263).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $34.85 · 2023: $324 · 2024: $384 · 2025: $457.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,164.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $205.20 | 2023-2025 | Fruzaqla, Iclusig, Entyvio |
| Janssen Biotech, INC. | $204.98 | 2023-2025 | Erleada, Akeega, Rybrevant |
| Novartis Pharmaceuticals Corporation | $184.92 | 2023-2025 | |
| Genentech USA, INC. | $164.55 | 2024-2025 | Alecensa, Tecentriq, Venclexta |
| Abbvie INC. | $123.74 | 2024-2025 | |
| Astellas Pharma US INC | $66.33 | 2023-2024 | Padcev |
| Deciphera Pharmaceuticals INC. | $62.42 | 2024-2025 | Qinlock, Romvimza, Tgct |
| Servier Pharmaceuticals LLC | $45.78 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $34.95 | 2023-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $34.85 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $24.92 | 2023 | Imbruvica, Epkinly |
| Ipsen Biopharmaceuticals, INC | $23.15 | 2025 | Onivyde |
| Amgen INC. | $23.13 | 2023 | Lumakras |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keni Horiuchi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.